ITIH5 and neoplasm: Additionally, ECRG4-ITIH5 in combination were able to distinguish bladder cancer patients from patients with neoplasms of other urological origin (control cohort 1b) with similar specificity (81.6%, AUC: 0.695, 95% CI: 0.631–0.760, p < 0.0001) but reduced sensitivity (50.9%) (Figure 3D).